PACS Heads Into Q3 Print With CEO Selling Into Strength

PACS Group reports Q3 results today with the market's attention drawn less to its positioning in the lending market and more to a steady stream of insider sales in the weeks before the print.

The CEO and co-founder, Jason Murray, sold more than $4.7 million worth of shares across five sessions between October 21 and October 29, all executed under a pre-arranged 10b5-1 trading plan. The Chief Accounting Officer and a director holding more than 33% of the company both sold alongside him. Net insider disposals over the past 90 days total roughly $60 million across 1.35 million shares. The 10b5-1 plan designation matters: these are scheduled sales, not discretionary signals of doubt, but the volume and timing, within two weeks of the print, is worth noting. Wikipedia views for PACS are running nearly three standard deviations above their own 90-day average, suggesting retail attention has spiked heading into today's release.

The debate among analysts who cover PACS centres on whether the company's internal investigation has permanently impaired its M&A pipeline or only delayed it. Bulls point to 2026 adjusted EBITDA guidance of $555 to $575 million and an addressable market in fragmented post-acute care that remains large and structurally attractive. Bears argue that the investigation creates execution risk around the acquisition strategy that underpins much of the growth case, and that uncertainty around timing makes the near-term outlook harder to underwrite. The Street's last consensus, struck in early September, carries a mean price target of $59, implying roughly 26% above the current $46.68. All recent analyst moves since August have been target raises, with UBS, Truist, RBC and Oppenheimer all lifting numbers after the Q2 print, though no major changes have come through in the two months since.

Short interest at 2.8% of the free float is not a primary story here. The borrow market is loose, with availability at 453%, meaning shares to borrow far outnumber shares already borrowed, and cost to borrow has stayed flat near 0.5% for weeks. Options positioning has edged slightly more defensive into earnings, with the put/call ratio at 0.15 against a 20-day average of 0.14, a move of roughly 1.6 standard deviations, but still at levels that reflect a structurally call-heavy market. The price closed at $46.68 on Monday, up 2.4% on the day but down 2.4% on the week, and roughly 9% higher over the past month.

Today's print is less a test of whether PACS can grow and more of whether management can demonstrate that the internal investigation is sufficiently resolved to restart meaningful deal activity without further operational disruption.